0 CHECKOUT

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

  • ID: 3215942
  • March 2015
  • 67 pages
  • Global Markets Direct
1 of 4

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

Summary:

This, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Interstitial Cystitis (Painful Bladder Syndrome) Overview
Therapeutics Development
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
Afferent Pharmaceuticals, Inc.
Allergan, Inc.
Aquinox Pharmaceuticals Inc.
Kytogenics Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc.
Qu Biologics Inc.
Urigen Pharmaceuticals, Inc.
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lidocaine + heparin) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AF-219 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AQX-1125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GM-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-5024 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QBECP-SSI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219
Jul 23, 2013: Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Apr 02, 2013: Taris Doses First Patient In Second Phase II Clinical Study Of LiRIS For Treatment Of Interstitial Cystitis
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients
Jun 30, 2011: Urigen Provides Development Update For URG101
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Afferent Pharmaceuticals, Inc.
- Allergan, Inc.
- Aquinox Pharmaceuticals Inc.
- Kytogenics Pharmaceuticals, Inc.
- Lipella Pharmaceuticals, Inc.
- Qu Biologics Inc.
- Urigen Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare